ArticleNPJ precision oncology2023
Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs.
Article in NPJ precision oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tyrosine kinase inhibitors and molecularly driven therapeutic approaches for canine lymphoma: a systematic review and meta-analysis.Frontiers in veterinary science · 2026Pooled it
- Preclinical study of an optimized AAV cancer vaccine in a spontaneous canine model of oral melanoma.Molecular therapy. Oncology · 2026Article
- Integrated Multiomic Profiling Enhances Risk Stratification and Prognostication in Canine Osteosarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Primer-walking sequencing identifies predominantly noncoding TP53 variants in canine cancers.Journal of veterinary science · 2026Article
- Leveraging Dog Models to Uncover Human Cancer Insights.Research square · 2026Article
- The oncogenome of the domestic cat.Science (New York, N.Y.) · 2026Article
- Editorial: Advances in drug development, residues management and emerging contaminants.Frontiers in veterinary science · 2026Article
- Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs.Chemical reviews · 2025Review
- PARP inhibitor olaparib induces DNA damage and acts as a drug sensitizer in an in vitro model of canine hematopoietic cancer.BMC veterinary research · 2025Article
- Evaluation of Cytokine Profile in Canine Malignant Oral Melanoma.Veterinary sciences · 2025Article
- Identification of novel genetic mutations for the treatment prognostication of canine lymphoma.NPJ precision oncology · 2025Article
- Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide-Tethered IL-12 in Dogs with Advanced Malignant Melanoma.Molecular cancer therapeutics · 2025Article
- Comparative pathophysiology and molecular insights into cutaneous and non-cutaneous canine skin cancers: focus on melanoma, mast cell tumors, and squamous cell carcinoma.Frontiers in immunology · 2025Review
- CD117 (KIT) in canine soft tissue sarcoma: an immunohistochemical and c-kit gene mutation assessment.Frontiers in veterinary science · 2025Article
- Case Report: Personalized, functional drug sensitivity-guided chemotherapy achieves long-term disease-free survival in canine pulmonary adenocarcinoma.Frontiers in veterinary science · 2025Article
- Some Aspects and Convergence of Human and Veterinary Drug Repositioning.Molecules (Basel, Switzerland) · 2024Review
- Tumor-Localized Interleukin-2 and Interleukin-12 Combine with Radiation Therapy to Safely Potentiate Regression of Advanced Malignant Melanoma in Pet Dogs.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- The K9 lymphoma assay allows a genetic subgrouping of canine lymphomas with improved risk classification.Scientific reports · 2024Article
- Bringing the Genomic Revolution to Comparative Oncology: Human and Dog Cancers.Annual review of biomedical data science · 2024Review
- Applications and Opportunities for Immune Cell CAR Engineering in Comparative Oncology.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spontaneous tumors in canines share significant genetic and histological similarities with human tumors, positioning them as valuable models to guide drug development. However, current translational studies have limited real world evidence as cancer outcomes are dispersed across veterinary clinics and genomic tests are rarely performed on dogs. In this study, we aim to expand the value of canine models by systematically characterizing genetic mutations in tumors and their response to targeted treatments. In total, we collect and analyze survival outcomes for 2119 tumor-bearing dogs and the prognostic effect of genomic alterations in a subset of 1108 dogs. Our analysis identifies prognostic concordance between canines and humans in several key oncogenes, including TP53 and PIK3CA. We also find that several targeted treatments designed for humans are associated with a positive prognosis when used to treat canine tumors with specific genomic alterations, underscoring the value of canine models in advancing drug discovery for personalized oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.